Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 4/20 | 0.44 |
| ▸ | AHCY | P23526 | 3/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.39 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20096664 | 0.86 | ATM (0.54) | DOT1LAHCYATMADORA1 | |
| SCHEMBL20096666 | 0.78 | DOT1L (0.56) | DOT1LAHCYNT5EADORA1 | |
| SCHEMBL20097216 | 0.77 | DOT1L (0.58) | DOT1LAHCYP2RX3P2RX4P2RX2 | |
| SCHEMBL20096659 | 0.74 | AHCY (0.55) | DOT1LAHCYPDE2ANT5EADORA1 | |
| SCHEMBL11427985 | 0.74 | PDE2A (0.64) | DOT1LAHCYPDE2AP2RX3P2RX4 | |
| SCHEMBL5961364 | 0.74 | PDE2A (0.64) | DOT1LAHCYPDE2AP2RX3P2RX4 | |
| SCHEMBL14429057 | 0.72 | PDE2A (0.59) | DOT1LAHCYPDE2AP2RX3P2RX4 | |
| SCHEMBL20097048 | 0.70 | AHCY (0.62) | DOT1LAHCYPDE2AP2RX3P2RX4 | |
| SCHEMBL20097049 | 0.70 | ADORA3 (0.51) | DOT1LAHCYADORA1 | |
| SCHEMBL6896076 | 0.70 | ADORA1 (0.66) | DOT1LAHCYADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-08-29 | — | — | US | disclosed |
| WO-2018075947-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RNA VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | POLRMT, EIF2AK2, NSUN3 | DOT1L 2274/4885AHCY 1888/4885PDE2A 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.